What your saying is right shady but that's due to a lack of clarity from the company. AHZ has told us what they won't be doing now tell us what you will be doing. That's the least they can do for the people who paid for it.
Sure they can have a few days or weeks but I'm expecting no more half speak. Clear and concise. What do these results mean and if there is a way forward what is it and what are the options. Personally I'd like the professor to come out of the shadows and answer the concerns and questions put to him by share holders in a public forum.
Is that to much to ask?
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-139
-
- There are more pages in this discussion • 212 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$12.19 |
Change
-0.010(0.08%) |
Mkt cap ! $257.6M | |||
| Open | High | Low | Value | Volume |
| $12.19 | $12.20 | $11.60 | $173.1K | 14.51K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9 | $11.97 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.19 | 28 | 1 |
View Market Depth
| Last trade - 16.10pm 01/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |